These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28533163)

  • 1. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors.
    Mullier B; Wolff C; Sands ZA; Ghisdal P; Muglia P; Kaminski RM; André VM
    Neuropharmacology; 2017 Sep; 123():322-331. PubMed ID: 28533163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.
    McKay S; Griffiths NH; Butters PA; Thubron EB; Hardingham GE; Wyllie DJ
    Br J Pharmacol; 2012 Jun; 166(3):924-37. PubMed ID: 22022974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold.
    Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B
    Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of GluN2A and GluN2B gain-of-function epilepsy mutations on synaptic currents mediated by diheteromeric and triheteromeric NMDA receptors.
    Chen X; Keramidas A; Harvey RJ; Lynch JW
    Neurobiol Dis; 2020 Jul; 140():104850. PubMed ID: 32247039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities for Precision Treatment of
    Han W; Yuan H; Allen JP; Kim S; Shaulsky GH; Perszyk RE; Traynelis SF; Myers SJ
    J Pharmacol Exp Ther; 2022 Apr; 381(1):54-66. PubMed ID: 35110392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome.
    Auvin S; Dozières-Puyravel B; Avbersek A; Sciberras D; Collier J; Leclercq K; Mares P; Kaminski RM; Muglia P
    Ann Clin Transl Neurol; 2020 Mar; 7(3):343-352. PubMed ID: 32106360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiprodil, a selective GluN2B negative allosteric modulator, rescues audiogenic seizures in mice carrying the GluN2A(N615S) mutation.
    Bertocchi I; Cifarelli L; Oberto A; Eva CE; Sprengel R; Mirza NR; Muglia P
    Br J Pharmacol; 2024 Jun; 181(12):1886-1894. PubMed ID: 38529699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Novel PET Tracer [
    van der Aart J; Yaqub M; Kooijman EJM; Bakker J; Langermans JAM; Schuit RC; Hofman MBM; Christiaans JAM; Lammertsma AA; Windhorst AD; van Berckel BNM
    Mol Imaging Biol; 2019 Aug; 21(4):676-685. PubMed ID: 30306318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.
    Yi F; Bhattacharya S; Thompson CM; Traynelis SF; Hansen KB
    J Physiol; 2019 Nov; 597(22):5495-5514. PubMed ID: 31541561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
    Fernandes A; Wojcik T; Baireddy P; Pieschl R; Newton A; Tian Y; Hong Y; Bristow L; Li YW
    Eur J Pharmacol; 2015 Nov; 766():1-8. PubMed ID: 26325093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits.
    Chatterton JE; Awobuluyi M; Premkumar LS; Takahashi H; Talantova M; Shin Y; Cui J; Tu S; Sevarino KA; Nakanishi N; Tong G; Lipton SA; Zhang D
    Nature; 2002 Feb; 415(6873):793-8. PubMed ID: 11823786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition.
    Wittekindt B; Malany S; Schemm R; Otvos L; Maccecchini ML; Laube B; Betz H
    Neuropharmacology; 2001 Nov; 41(6):753-61. PubMed ID: 11640930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptic NMDA receptors in basolateral amygdala principal neurons are triheteromeric proteins: physiological role of GluN2B subunits.
    Delaney AJ; Sedlak PL; Autuori E; Power JM; Sah P
    J Neurophysiol; 2013 Mar; 109(5):1391-402. PubMed ID: 23221411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms.
    Ragnarsson L; Zhang Z; Das SS; Tran P; Andersson Å; des Portes V; Desmettre Altuzarra C; Remerand G; Labalme A; Chatron N; Sanlaville D; Lesca G; Anggono V; Vetter I; Keramidas A
    Epilepsia; 2023 Dec; 64(12):3377-3388. PubMed ID: 37734923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties.
    Fedele L; Newcombe J; Topf M; Gibb A; Harvey RJ; Smart TG
    Nat Commun; 2018 Mar; 9(1):957. PubMed ID: 29511171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials.
    Randle JC; Guet T; Bobichon C; Moreau C; Curutchet P; Lambolez B; de Carvalho LP; Cordi A; Lepagnol JM
    Mol Pharmacol; 1992 Feb; 41(2):337-45. PubMed ID: 1371583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.
    Hansen KB; Mullasseril P; Dawit S; Kurtkaya NL; Yuan H; Vance KM; Orr AG; Kvist T; Ogden KK; Le P; Vellano KM; Lewis I; Kurtkaya S; Du Y; Qui M; Murphy TJ; Snyder JP; Bräuner-Osborne H; Traynelis SF
    J Pharmacol Exp Ther; 2010 Jun; 333(3):650-62. PubMed ID: 20197375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
    Kleckner NW; Glazewski JC; Chen CC; Moscrip TD
    J Pharmacol Exp Ther; 1999 May; 289(2):886-94. PubMed ID: 10215667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.
    Ballard TM; Pauly-Evers M; Higgins GA; Ouagazzal AM; Mutel V; Borroni E; Kemp JA; Bluethmann H; Kew JN
    J Neurosci; 2002 Aug; 22(15):6713-23. PubMed ID: 12151550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors.
    Hansen KB; Ogden KK; Yuan H; Traynelis SF
    Neuron; 2014 Mar; 81(5):1084-1096. PubMed ID: 24607230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.